logo-loader
Akari Therapeutics

Akari Therapeutics expects readouts from two key Phase II studies by year-end

Clive Richardson, chief executive of Akari Therapeutics PLC (NASDAQ:AKTX), introduces the business to Proactive London and outlines some of the work they're doing in the area of acute and chronic inflammation.

Discussing their protein Nomacopan, he says it's currently being clinically evaluated in four indications including a severe blistering skin disease and a sight threatening surface of the eye condition.

Quick facts: Akari Therapeutics

Price: 1.7 USD

Market: NASDAQ
Market Cap: $35.71 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics to present data showing Feraccru offers 'real oral...

Shield Therapeutics PLC's (LON:STX) Dr Mark Sampson speaks to Proactive London's Andrew Scott ahead of them presenting positive data from the Phase 3b, open-label randomised controlled trial of Feraccru. He says the trial shows the drug, also known as Accrufer in the States, offers a real...

14 hours, 48 minutes ago

2 min read